Clinical Trial Update: Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of AZD8848 in individuals with butyrylcholinesterase deficiency; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Butyrylcholinesterase Deficiency

Drugs mentioned

• AZD8848

Snippet

Sponsor: AstraZeneca | Conditions: Butyrylcholinesterase Deficiency | Phase 1 | Status: COMPLETED